Session recorded on August 21, 2017.
Speaker: Mark S. Dykewicz, MD
Viewers can earn credit by completing the posttest questions.
New evidence based rhinitis treatment guidelines in press by (1) Joint Task Force for Practice Parameters of AAAAI and ACAAI and (2) ARIA, both based upon GRADE analysis (Grading of Recommendations, Assessment, Development and Evaluations) need to be disseminated. Recommendations include discouraging use of commonly used treatment strategies (e.g. combination of oral antihistamine and intranasal corticosteroids) for which there is little evidence basis. These new recommendations need to presented in broader context of available knowledge and treatment options. This video covers the defintion and importance of rhinitis. It covers allergic and non-allergic rhinitis, along with differential considerations, diagnosis, and treatment.
Practicing Allergists / Immunologists
After viewing the video recording, learners should be able to…
- Distinguish between allergic and non-allergic forms of rhinitis, and differential considerations
- Select pharmacologic monotherapy and combination therapy for allergic and non-allergic rhinitis
- Describe process and deliberations used to establish recent evidence-based guideline recommendations for rhinitis
Mark S. Dykewicz, MD
Raymond & Alberta Slavin Endowed Professor in Allergy & Immunology
Professor of Internal Medicine
Chief, Section of Allergy and Immunology
Division of Infectious Diseases, Allergy & Immunology
Department of Internal Medicine
Director, Allergy and Immunology Fellowship Program
Saint Louis University
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no commercial support for this activity.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance